Nothing Special   »   [go: up one dir, main page]

ES2656000T3 - Anticuerpos frente a CGRP - Google Patents

Anticuerpos frente a CGRP Download PDF

Info

Publication number
ES2656000T3
ES2656000T3 ES11792989.3T ES11792989T ES2656000T3 ES 2656000 T3 ES2656000 T3 ES 2656000T3 ES 11792989 T ES11792989 T ES 11792989T ES 2656000 T3 ES2656000 T3 ES 2656000T3
Authority
ES
Spain
Prior art keywords
seq
antibodies against
lcdr3
lcdr1
lcdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11792989.3T
Other languages
English (en)
Inventor
Barrett Allan
Robert Jan Benschop
Mark Geoffrey Chambers
Ryan James Darling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2656000T3 publication Critical patent/ES2656000T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57527Calcitonin gene related peptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57545Neuropeptide Y
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57563Vasoactive intestinal peptide [VIP]; Related peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un anticuerpo frente a CGRP humano técnicamente diseñado que comprende una región variable de la cadena ligera (LCVR) y una región variable de la cadena pesada (HCVR), en el que dicha LCVR comprende las secuencias de aminoácidos de LCDR1, LCDR2, LCDR3 y la HCVR comprende las secuencias de aminoácidos de HCDR1, HCDR2, HCDR3, en el que LCDR1 es RASKDISKYLN (SEQ ID NO: 6), LCDR2 es YTSGYHS (SEQ ID NO: 7), LCDR3 es QQGDALPPT (SEQ ID NO: 5), HCDR1 es GYTFGNYWMQ (SEQ ID NO: 12), HCDR2 es AIYEGTGKTVYIQKFAD (SEQ ID NO: 16) y HCDR3 es LSDYVSGFGY (SEQ ID NO: 39).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
X1 es Q, R o K; X2 es D o P; X3 es D o S; X4 es N o K; y X5 es G o E.
Anticuerpo
LCDR1 LCDR2 LCDR3
I
GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGDTRYIQKFAG (SEQ ID NO: 13) LSDYVSGFSY (SEQ ID NO:14)
II
GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGKTVYIQKFAG (SEQ ID NO: 15 LSDYVSGFSY (SEQ ID NO:14)
III
GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGKTVYIQKFAD (SEQ ID NO: 16) LSDYVSGFGY (SEQ ID NO:39)
IV
GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGKTVYIQKFAG (SEQ ID NO: 15) LSDYVSGFGY (SEQ ID NO:39)
V
GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGKTVYIQKFAG (SEQ ID NO: 15) LSDYVSGFGY (SEQ ID NO:39)
consenso
GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGX6TX7YIQKFAX8 (SEQ ID NO:37) LSDYVSGFX9Y (SEQ ID NO:38)
X6 es K o D; X7 es V o R; X8 es D oG; y X9 es G o S.
imagen10
11
imagen11
imagen12
imagen13
imagen14

Claims (1)

  1. imagen1
ES11792989.3T 2010-06-10 2011-06-07 Anticuerpos frente a CGRP Active ES2656000T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35332310P 2010-06-10 2010-06-10
US353323P 2010-06-10
PCT/US2011/039381 WO2011156324A1 (en) 2010-06-10 2011-06-07 Cgrp antibodies

Publications (1)

Publication Number Publication Date
ES2656000T3 true ES2656000T3 (es) 2018-02-22

Family

ID=45096388

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17201603T Active ES2930321T3 (es) 2010-06-10 2011-06-07 Anticuerpos frente a CGRP
ES11792989.3T Active ES2656000T3 (es) 2010-06-10 2011-06-07 Anticuerpos frente a CGRP

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES17201603T Active ES2930321T3 (es) 2010-06-10 2011-06-07 Anticuerpos frente a CGRP

Country Status (34)

Country Link
US (3) US9073991B2 (es)
EP (2) EP2579894B1 (es)
JP (2) JP6021806B2 (es)
KR (1) KR101489566B1 (es)
CN (2) CN104292332B (es)
AR (1) AR081434A1 (es)
AU (1) AU2011265050B2 (es)
BR (1) BR112012031501B1 (es)
CA (1) CA2802102C (es)
CY (2) CY1119789T1 (es)
DK (1) DK2579894T3 (es)
EA (1) EA022931B1 (es)
ES (2) ES2930321T3 (es)
HK (1) HK1203211A1 (es)
HR (1) HRP20171992T1 (es)
HU (2) HUE038135T2 (es)
IL (2) IL222885B (es)
JO (1) JO3330B1 (es)
LT (2) LT2579894T (es)
LU (1) LUC00112I2 (es)
ME (1) ME02862B (es)
MX (2) MX363209B (es)
NL (1) NL300979I2 (es)
NO (2) NO2579894T3 (es)
NZ (1) NZ603607A (es)
PL (1) PL2579894T3 (es)
PT (1) PT2579894T (es)
RS (1) RS56638B1 (es)
SG (1) SG185648A1 (es)
SI (1) SI2579894T1 (es)
TW (1) TWI423818B (es)
UA (1) UA109658C2 (es)
WO (1) WO2011156324A1 (es)
ZA (1) ZA201208996B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3842458A1 (en) 2005-11-14 2021-06-30 Teva Pharmaceuticals International GmbH Antagonist antibodies directed against calcitonin gene-related peptide
EP3441087A1 (en) 2008-03-04 2019-02-13 Teva Pharmaceuticals International GmbH Methods of treating chronic pain
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
US9708393B2 (en) 2011-05-20 2017-07-18 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
WO2012162243A2 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
JP6568099B2 (ja) 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6581656B2 (ja) 2014-10-24 2019-09-25 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. グルカゴンおよびglp−1受容体のコアゴニスト
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
JP6592600B2 (ja) * 2015-10-30 2019-10-16 イーライ リリー アンド カンパニー 抗cgrp/抗il−23二重特異性抗体及びその使用
CN105483091A (zh) * 2015-12-29 2016-04-13 天津三箭生物技术股份有限公司 小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
JP2019501152A (ja) * 2016-01-28 2019-01-17 イーライ リリー アンド カンパニー Cgrp抗体及びその使用
EP3411066A1 (en) 2016-02-01 2018-12-12 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds
CN109996544A (zh) 2016-06-27 2019-07-09 加利福尼亚大学董事会 癌症治疗组合
EP3515937A1 (en) * 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Treating refractory migraine
US20180111984A1 (en) 2016-09-23 2018-04-26 Teva Pharmaceuticals International Gmbh Treating cluster headache
MX2019010397A (es) 2017-03-02 2020-08-20 Beth Israel Deaconess Medical Ct Inc Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
TW201902926A (zh) * 2017-05-03 2019-01-16 美商美國禮來大藥廠 抗cgrp/抗il-23雙特異性抗體及其用途
EP3642218A4 (en) * 2017-06-21 2021-04-07 Cephalon, Inc. CATION EXCHANGE CHROMATOGRAPHY WASH PAD
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
UY38050A (es) 2018-01-12 2019-07-31 Amgen Inc Anticuerpos pac1 y sus usos referencia cruzada a solicitudes relacionadas
WO2019231800A1 (en) 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
WO2020041468A1 (en) 2018-08-22 2020-02-27 Eli Lilly And Company Anti-cgrp antibodies for treatment-resistant patients
CN113227140A (zh) 2019-01-08 2021-08-06 H.隆德贝克有限公司 使用抗cgrp抗体急性治疗和快速治疗头痛
EP3744400A1 (en) * 2019-05-28 2020-12-02 Etablissement Français du Sang Car-t cells targeting il-1rap and their use in acute myeloid leukemia (aml)
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
JP7551744B2 (ja) 2019-10-15 2024-09-17 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ/エステラーゼ欠損哺乳動物細胞株
CA3212151A1 (en) 2021-03-02 2022-09-09 Cgrp Diagnostics Gmbh Treatment and/or reduction of occurrence of migraine
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
CN117586390A (zh) * 2022-08-11 2024-02-23 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途
CN118271438B (zh) * 2024-05-27 2024-08-30 上海宏成药业有限公司 抗cgrp抗体或其抗原结合片段及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
RU2139351C1 (ru) * 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US20060228367A1 (en) * 2005-04-08 2006-10-12 Medimmune, Inc. Antibodies against mammalian metapneumovirus
EP3842458A1 (en) * 2005-11-14 2021-06-30 Teva Pharmaceuticals International GmbH Antagonist antibodies directed against calcitonin gene-related peptide
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
EP3441087A1 (en) * 2008-03-04 2019-02-13 Teva Pharmaceuticals International GmbH Methods of treating chronic pain
EP3115062A1 (en) 2008-03-04 2017-01-11 Labrys Biologics Inc. Methods of treating inflammatory pain
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp

Also Published As

Publication number Publication date
NL300979I1 (nl) 2019-04-17
US20150259415A1 (en) 2015-09-17
EP3318272A1 (en) 2018-05-09
JO3330B1 (ar) 2019-03-13
US9505838B2 (en) 2016-11-29
CN104292332A (zh) 2015-01-21
JP2017014203A (ja) 2017-01-19
HK1203211A1 (en) 2015-10-23
MX340999B (es) 2016-08-03
EP2579894B1 (en) 2017-11-22
LT2579894T (lt) 2018-02-26
TWI423818B (zh) 2014-01-21
PL2579894T3 (pl) 2018-04-30
CA2802102A1 (en) 2011-12-15
JP6466883B2 (ja) 2019-02-06
IL222885B (en) 2019-09-26
NO2019017I1 (no) 2019-04-05
LUC00112I2 (es) 2019-12-27
NZ603607A (en) 2014-09-26
US9073991B2 (en) 2015-07-07
HUE038135T2 (hu) 2018-09-28
KR20130034024A (ko) 2013-04-04
US20110305711A1 (en) 2011-12-15
IL222885A0 (en) 2012-12-31
IL242409B (en) 2020-07-30
CY2019017I1 (el) 2020-05-29
ES2930321T3 (es) 2022-12-09
TW201210618A (en) 2012-03-16
RS56638B1 (sr) 2018-03-30
WO2011156324A1 (en) 2011-12-15
CA2802102C (en) 2016-07-26
US20170073403A1 (en) 2017-03-16
DK2579894T3 (en) 2018-01-15
UA109658C2 (xx) 2015-09-25
CY2019017I2 (el) 2020-05-29
LUC00112I1 (es) 2019-04-10
BR112012031501B1 (pt) 2020-02-11
CN102946905B (zh) 2014-10-15
EP2579894A1 (en) 2013-04-17
EP3318272B1 (en) 2022-08-10
MX363209B (es) 2019-03-14
AU2011265050B2 (en) 2013-06-27
SG185648A1 (en) 2012-12-28
HRP20171992T1 (hr) 2018-02-09
AU2011265050A1 (en) 2012-11-08
CN102946905A (zh) 2013-02-27
KR101489566B1 (ko) 2015-02-03
EA201270769A1 (ru) 2013-04-30
JP6021806B2 (ja) 2016-11-09
SI2579894T1 (en) 2018-01-31
MX2012014480A (es) 2013-02-07
ME02862B (me) 2018-04-20
JP2013532143A (ja) 2013-08-15
CN104292332B (zh) 2019-11-01
NL300979I2 (nl) 2019-07-11
EP2579894A4 (en) 2013-12-04
LTPA2019011I1 (lt) 2019-05-10
LTC2579894I2 (lt) 2020-03-25
EA022931B1 (ru) 2016-03-31
AR081434A1 (es) 2012-08-29
PT2579894T (pt) 2018-02-06
BR112012031501A2 (pt) 2016-10-25
NO2579894T3 (es) 2018-04-21
HUS1900020I1 (hu) 2019-05-28
ZA201208996B (en) 2014-05-28
CY1119789T1 (el) 2018-06-27

Similar Documents

Publication Publication Date Title
ES2656000T3 (es) Anticuerpos frente a CGRP
ES2564252T3 (es) Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
HRP20211343T1 (hr) Protutijela protiv dkk-1
PE20210045A1 (es) Anticuerpos agonistas contra pd-1 y usos de estos
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
AR081427A1 (es) Metodo para preparar anticuerpos con propiedades mejoradas
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20141151A1 (es) Proteinas de union al antigeno cd27l
RS54111B1 (en) ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
ES2685823T3 (es) Anticuerpos antagonistas anti-CD40
PE20191408A1 (es) Proteinas de union a antigeno st2
PE20091261A1 (es) Anticuerpos anti-hepcidina
NZ628943A (en) Human antibodies to clostridium difficile toxins
RU2011142183A (ru) Средство для лечения ревматоидного артрита
PE20220708A1 (es) Anticuerpos anti-cd73
HRP20161587T1 (hr) Protutijela protiv bmp-6
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)
PE20201494A1 (es) Anticuerpo anti-pacap